Welcome to our dedicated page for Pfizer SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pfizer Inc. (PFE) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, with AI‑powered tools to help interpret complex documents. As a large issuer in the pharmaceutical preparation manufacturing industry, Pfizer files a wide range of reports that are important for understanding its operations, capital structure and risk profile.
Investors can review Form 8‑K current reports that describe material events such as financial results, public offerings of notes, acquisitions and guidance updates. Recent 8‑K filings detail second‑ and third‑quarter 2025 financial results, full‑year 2025 and 2026 revenue and adjusted EPS guidance, a multi‑tranche public offering of senior notes with maturities extending to 2065, and the completed acquisition of Metsera, a company developing GLP‑1‑based obesity therapies.
Pfizer’s 8‑Ks also reference shelf registration statements and supplemental indentures governing its debt securities, as well as underwriting and pricing agreements with major investment banks. These filings help users track how Pfizer raises long‑term capital and manages its balance sheet. Other 8‑Ks furnish press releases under Regulation FD, including guidance updates that outline expected revenue contributions from COVID‑19 products and the impact of loss of exclusivity on certain medicines.
On Stock Titan, AI‑generated summaries highlight the key points of lengthy filings, explaining in plain language what new debt offerings, acquisitions, guidance changes or other events may mean for the company. Users can quickly identify which exhibits relate to indentures, legal opinions or merger agreements, and can follow how Pfizer’s financing activities and strategic transactions evolve over time.
In addition to 8‑Ks, this page links to Pfizer’s other core SEC reports, such as annual and quarterly filings, where available. Together, these documents provide a regulatory record of Pfizer’s financial performance, risk factors, capital markets activity and major corporate actions, with AI assistance to make the information more accessible.
Pfizer Inc director Shantanu Narayen reported acquiring 2,008.032 phantom stock units on Pfizer common stock as of 12/31/2025. Each unit represents one phantom share of common stock tied to deferred director compensation, including dividend equivalents.
These units are to be settled in cash or common stock at the director's election after retirement from the Board of Directors. Following this transaction, Narayen beneficially owned 183,164.359 derivative securities related to Pfizer common stock, recorded at a derivative security price of $24.9.
Pfizer Inc. director reports phantom stock unit grant tied to board compensation. On 12/31/2025, a reporting person serving as a Pfizer director acquired 1,556.225 phantom stock units linked to Pfizer common stock at a price of
Pfizer Inc. director reports additional deferred compensation in phantom stock units. On 12/31/2025, director James C. Smith acquired 1,807.229 phantom stock units tied to Pfizer common stock at a derivative security price of $24.9. After this transaction, he beneficially owned 166,119.84 derivative securities directly.
Each phantom stock unit represents one phantom share of Pfizer common stock. These units reflect deferred director compensation, including dividend equivalents, and will be settled in cash or common stock at the director’s election after he retires from the Board of Directors. The filing reports an acquisition of compensation-linked units rather than an open-market stock sale.
Pfizer Inc. director compensation update: A Pfizer Inc. (PFE) director reported receiving 1,506.024 phantom stock units on 12/31/2025 as part of deferred director compensation. Each unit represents one phantom share of common stock, with the units to be settled in cash or common stock at the director's election following retirement from the Board of Directors. After this transaction, the director beneficially owned 25,349.741 phantom stock units, held in direct form.
Pfizer Inc. Chairman and CEO Albert Bourla, who also serves as a director of Pfizer Inc. (PFE), reported a routine change in his deferred compensation holdings as of 12/31/2025. The filing shows the acquisition of 24 Phantom Stock Units SSP, a type of derivative security that tracks Pfizer common stock.
Each phantom unit represents one phantom share of Pfizer common stock and is part of the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. These units are settled in cash after Bourla’s separation from service and may be moved into an alternative investment account at any time. Following this transaction, he beneficially owns 743,147 derivative securities related to these phantom stock units on a direct basis.
Pfizer Inc. Chairman and CEO Albert Bourla reported acquiring 23 phantom stock units linked to Pfizer common stock on 12/15/2025 under a deferred compensation plan.
Each unit represents one phantom share and is settled in cash after his separation from service. Following this transaction, Bourla beneficially owned 742,986 phantom stock units directly.
Pfizer Inc. furnished a regulatory disclosure stating that it issued a press release providing its full-year 2026 financial guidance and revising its full-year 2025 revenue guidance.
The company reaffirmed all other components of its full-year 2025 financial guidance in the same press release, which is attached as an exhibit to the disclosure.
Pfizer Inc. Chairman and CEO Albert Bourla reported an insider equity transaction involving company-linked deferred compensation. On 11/28/2025, he acquired 23 Phantom Stock Units SSP, each representing one phantom share of Pfizer common stock at a reference price of $25.74 per unit. Following this transaction, he beneficially owns 743,115 phantom stock units.
The units were acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. They are settled in cash after Bourla’s separation from service and may be moved by him into an alternative investment account at any time. The filing is made by one reporting person in his roles as both director and Chairman & CEO.
Pfizer Inc. completed a multi-tranche public notes offering, issuing $500,000,000 of Floating Rate Notes due 2027 and several series of fixed-rate notes with maturities from 2027 to 2065. The fixed-rate tranches include $1,000,000,000 of 3.875% Notes due 2027, $1,000,000,000 of 4.200% Notes due 2030, $1,250,000,000 of 4.500% Notes due 2032, $1,250,000,000 of 4.875% Notes due 2035, $500,000,000 of 5.600% Notes due 2055 and $500,000,000 of 5.700% Notes due 2065. The notes were issued under Pfizer’s existing shelf registration statement and an indenture with The Bank of New York Mellon, with Citigroup, Deutsche Bank, J.P. Morgan and Mizuho acting as lead underwriters.
Pfizer Inc. is issuing $500 million of floating-rate notes due 2027 and $5.5 billion of fixed-rate notes maturing between 2027 and 2065. The fixed-rate tranches carry coupons of 3.875% (2027), 4.200% (2030), 4.500% (2032), 4.875% (2035), 5.600% (2055) and 5.700% (2065), with interest paid semi-annually, while the floating-rate notes pay quarterly interest at Compounded SOFR plus 0.500%. The notes are unsecured, unsubordinated obligations ranking equally with Pfizer’s other unsubordinated debt and have no sinking fund.
Pfizer expects net proceeds of approximately $5,966,010,000 after underwriting discounts, to be used for general corporate purposes, including funding the acquisition of Metsera and refinancing existing indebtedness. Fixed-rate notes are callable at Pfizer’s option (subject to make‑whole and par call features), while the floating-rate notes are not redeemable before maturity. The notes will not be listed on any securities exchange, and Pfizer highlights risks around subordination to secured and subsidiary debt, benchmark rate reform and SOFR-related volatility for the floating‑rate series.